These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 15954852

  • 1. Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles.
    Jacobs MR.
    Expert Rev Anti Infect Ther; 2005 Jun; 3(3):353-60. PubMed ID: 15954852
    [Abstract] [Full Text] [Related]

  • 2. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B.
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [Abstract] [Full Text] [Related]

  • 3. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM, Jacobs MR, Good CE, Bajaksouzian S, Windau A, Jakielaszek C, Saunders KA.
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM, Garau J, Jacobs MR, Wynne B, Twynholm M, Berkowitz E.
    Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
    [Abstract] [Full Text] [Related]

  • 5. Evolution of amoxicillin/clavulanate in the treatment of adults with acute bacterial rhinosinusitis and community-acquired pneumonia in response to antimicrobial-resistance patterns.
    File TM, Benninger MS, Jacobs MR.
    Clin Lab Med; 2004 Jun; 24(2):531-51. PubMed ID: 15177852
    [Abstract] [Full Text] [Related]

  • 6. The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults.
    File TM.
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S131-4. PubMed ID: 18029151
    [Abstract] [Full Text] [Related]

  • 7. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L.
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [Abstract] [Full Text] [Related]

  • 8. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate.
    Sader HS, Jacobs MR, Fritsche TR.
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3 Suppl):5S-12S. PubMed ID: 17292577
    [Abstract] [Full Text] [Related]

  • 9. Eradication of pathogens from the nasopharynx after therapy of acute maxillary sinusitis with low- or high-dose amoxicillin/clavulanic acid.
    Brook I, Foote PA, Hausfeld JN.
    Int J Antimicrob Agents; 2005 Nov; 26(5):416-9. PubMed ID: 16226017
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B, Sánchez-Alvarez J, García-Mendez E, Sabriá M, Santos J, Pallarés R, Twynholm M, Dal-Ré R, 620 Clinical Study Group.
    J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
    [Abstract] [Full Text] [Related]

  • 11. Amoxicillin/clavulanate potassium extended release tablets: a new antimicrobial for the treatment of acute bacterial sinusitis and community-acquired pneumonia.
    Benninger MS.
    Expert Opin Pharmacother; 2003 Oct; 4(10):1839-46. PubMed ID: 14521493
    [Abstract] [Full Text] [Related]

  • 12. Resistant respiratory pathogens and extended-spectrum antibiotics.
    Pichichero ME.
    Am Fam Physician; 1995 Nov 01; 52(6):1739-46. PubMed ID: 7484684
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis.
    Sethi S, Breton J, Wynne B.
    Antimicrob Agents Chemother; 2005 Jan 01; 49(1):153-60. PubMed ID: 15616290
    [Abstract] [Full Text] [Related]

  • 14. Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media.
    Easton J, Noble S, Perry CM.
    Drugs; 2003 Jan 01; 63(3):311-40. PubMed ID: 12534334
    [Abstract] [Full Text] [Related]

  • 15. [Amoxicillin/clavulanic acid (875/125 mg). New pharmacodynamic aspects].
    Lode H.
    Dtsch Med Wochenschr; 1999 Dec 03; 124(48):1459-61. PubMed ID: 10615328
    [No Abstract] [Full Text] [Related]

  • 16. Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?
    Pottumarthy S, Sader HS, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Nov 03; 53(3):225-31. PubMed ID: 16257168
    [Abstract] [Full Text] [Related]

  • 17. The clinical development and launch of amoxicillin/clavulanate for the treatment of a range of community-acquired infections.
    Ball P.
    Int J Antimicrob Agents; 2007 Dec 03; 30 Suppl 2():S113-7. PubMed ID: 17997283
    [Abstract] [Full Text] [Related]

  • 18. The use of pharmacokinetic/pharmacodynamic principles to predict clinical outcome in paediatric acute otitis media.
    Dagan R.
    Int J Antimicrob Agents; 2007 Dec 03; 30 Suppl 2():S127-30. PubMed ID: 17980558
    [Abstract] [Full Text] [Related]

  • 19. Building in efficacy: developing solutions to combat drug-resistant S. pneumoniae.
    Jacobs MR.
    Clin Microbiol Infect; 2004 Apr 03; 10 Suppl 2():18-27. PubMed ID: 14759230
    [Abstract] [Full Text] [Related]

  • 20. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
    Harrison CJ, Woods C, Stout G, Martin B, Selvarangan R.
    J Antimicrob Chemother; 2009 Mar 03; 63(3):511-9. PubMed ID: 19174454
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.